Pasatru™ (garetosmab-grts) First and Only FDA-approved Treatment Demonstrating Reduction in New Heterotopic Ossification (HO) Lesions and Clinician-Assessed Flare-ups in a Placebo-controlled Trial i
Go back to Pasatru™ (garetosmab-grts) First and Only FDA-approved Treatment Demonstrating Reduction in New Heterotopic Ossification (HO) Lesions and Clinician-Assessed Flare-ups in a Placebo-controlled Trial i| Regeneron (NASDAQ: REGN) | Delayed: 827.72 -15.75 (1.87%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $843.47 | 52 Week High | $592.36 | |||
| Open | $840.05 | 52 Week Low | $325.35 | |||
| Day High | $841.54 | P/E | 217.25 | |||
| Day Low | $825.83 | EPS | $3.81 | |||
| Volume | 561,167 | |||||
